Connect
MJA
MJA

The Heart Protection Study: implications for clinical practice

Ian Hamilton-Craig
Med J Aust 2002; 177 (8): . || doi: 10.5694/j.1326-5377.2002.tb04877.x
Published online: 21 October 2002

The benefits of statin therapy do not come without financial cost

The aim of the recently reported Heart Protection Study1 in the United Kingdom, with over 20 000 participants aged 40–80 years, was to establish whether statin therapy is of benefit to people who are at high risk of cardiovascular disease (CVD) but have average-to-low levels of total cholesterol and LDL-cholesterol. High-risk patients (defined as those having previous coronary heart disease, diabetes, stroke, or peripheral vascular disease) were treated with simvastatin (40 mg daily), antioxidant vitamins (20 mg beta-carotene, 250 mg vitamin C and 600 mg vitamin E daily) or placebo in a 2 × 2 factorial design.


  • North Adelaide Cardiac Clinic, North Adelaide, SA.


Correspondence: ihc@medped-aust.com

Competing interests:

The author has served in an advisory capacity to government and non-government bodies, including pharmaceutical companies, and has received support for clinical research, presentations and attendance at scientific meetings from these bodies.

  • 1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
  • 2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
  • 3. Yusuf S. Two decades of preventing vascular disease. Lancet 2002; 360: 2-3.
  • 4. National Prescribing Service. Dyslipidaemia — background material. Sydney: National Prescribing Service Limited, 2002.
  • 5. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
  • 6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
  • 7. Saltissi D, Morgan C, Rigby RJ, Westhuysen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39: 369-375.
  • 8. Masterson TM. Safety and efficacy of simvastatin in patients undergoing chronic renal dialysis: are we ready to treat hypercholesterolemia? Am J Kidney Dis 2002; 39: 419-421.
  • 9. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175: 486-489.
  • 10. Iso H, Jacobs DR Jr, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-910.
  • 11. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000; 132: 769-779.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.